vs
Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and A2Z CUST2MATE SOLUTIONS CORP. (AZ). Click either name above to swap in a different company.
A2Z CUST2MATE SOLUTIONS CORP. is the larger business by last-quarter revenue ($1.5M vs $1.0M, roughly 1.5× Applied Therapeutics, Inc.). A2Z CUST2MATE SOLUTIONS CORP. runs the higher net margin — -90.4% vs -1899.0%, a 1808.6% gap on every dollar of revenue. On growth, Applied Therapeutics, Inc. posted the faster year-over-year revenue change (719.7% vs -1.6%).
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
APLT vs AZ — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.5M |
| Net Profit | $-19.0M | $-1.4M |
| Gross Margin | — | 34.0% |
| Operating Margin | -1675.8% | -265.9% |
| Net Margin | -1899.0% | -90.4% |
| Revenue YoY | 719.7% | -1.6% |
| Net Profit YoY | 72.3% | 60.4% |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.0M | $1.5M | ||
| Q2 25 | $0 | $1.2M | ||
| Q1 25 | $0 | $2.0M | ||
| Q4 24 | $-1.0K | — | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $144.0K | $1.1M | ||
| Q1 24 | $190.0K | — | ||
| Q4 23 | $-667.0K | — |
| Q3 25 | $-19.0M | $-1.4M | ||
| Q2 25 | $-21.3M | $-12.6M | ||
| Q1 25 | $-21.8M | $-6.8M | ||
| Q4 24 | $44.0M | — | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | $2.9M | $-3.2M | ||
| Q1 24 | $-83.9M | — | ||
| Q4 23 | $-37.7M | — |
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 23.3% | ||
| Q1 25 | — | 31.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 43.9% | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | -1675.8% | -265.9% | ||
| Q2 25 | — | -585.9% | ||
| Q1 25 | — | -381.4% | ||
| Q4 24 | 3302300.0% | — | ||
| Q3 24 | — | -167.0% | ||
| Q2 24 | -14194.4% | -272.1% | ||
| Q1 24 | -11101.6% | — | ||
| Q4 23 | 3149.3% | — |
| Q3 25 | -1899.0% | -90.4% | ||
| Q2 25 | — | -1085.4% | ||
| Q1 25 | — | -342.1% | ||
| Q4 24 | -4400700.0% | — | ||
| Q3 24 | — | -224.7% | ||
| Q2 24 | 2012.5% | -277.4% | ||
| Q1 24 | -44177.9% | — | ||
| Q4 23 | 5649.0% | — |
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.15 | $-0.19 | ||
| Q4 24 | $0.52 | — | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | $-0.13 | $-0.05 | ||
| Q1 24 | $-0.67 | — | ||
| Q4 23 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.9M | $43.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-561.0K | $71.3M |
| Total Assets | $34.4M | $81.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $11.9M | $43.2M | ||
| Q2 25 | $30.4M | $28.5M | ||
| Q1 25 | $50.8M | $24.2M | ||
| Q4 24 | $79.4M | — | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | $122.2M | $653.0K | ||
| Q1 24 | $146.5M | — | ||
| Q4 23 | $49.9M | — |
| Q3 25 | $-561.0K | $71.3M | ||
| Q2 25 | $17.4M | $31.5M | ||
| Q1 25 | $36.7M | $31.3M | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | — | $-504.0K | ||
| Q2 24 | $72.4M | $-340.0K | ||
| Q1 24 | $67.3M | — | ||
| Q4 23 | $-17.1M | — |
| Q3 25 | $34.4M | $81.9M | ||
| Q2 25 | $37.3M | $46.1M | ||
| Q1 25 | $56.9M | $42.2M | ||
| Q4 24 | $86.7M | — | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | $127.8M | $7.2M | ||
| Q1 24 | $151.2M | — | ||
| Q4 23 | $54.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.4M | $-4.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-18.4M | $-4.0M | ||
| Q2 25 | $-20.3M | $-5.9M | ||
| Q1 25 | $-28.6M | $-3.8M | ||
| Q4 24 | $-19.5M | — | ||
| Q3 24 | — | $-658.0K | ||
| Q2 24 | $-22.6M | $-3.7M | ||
| Q1 24 | $-18.9M | — | ||
| Q4 23 | $-17.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.44× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -7.80× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
